WASHINGTON (Reuters) - Celgene Corp. won U.S. approval on Thursday to promote its drug Thalomid for treating patients newly diagnosed with the blood cancer multiple myeloma.
The drug, known generically as thalidomide, already is widely used in multiple myeloma but had been officially cleared only to treat leprosy. Distribution is tightly controlled to prevent pregnant women from taking the drug and risking birth defects, but doctors are free to prescribe it as they see fit.
Already a subscriber? Log in.
Win a prize this Mother's Day by subscribing to our annual plan now! T&C applies.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
